Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity. (CHOC-LATE Trial)

NCT07164534 is registered in ClinicalTrials.gov with Tata Memorial Hospital as lead sponsor.

NCT NCT07164534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07164534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity. (CHOC-LATE Trial)
Lead sponsor
Tata Memorial Hospital
Phase
Phase 3
Overall status
Not yet recruiting
Start date
March 31, 2026
Completion date
September 30, 2030
Enrollment
316 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

uterine cervical neoplasm